



**Susan Catalano, Ph.D.**

Chief Science Officer and Founder  
Cognition Therapeutics, Inc.

Susan Catalano, Ph.D. is the founder of Cognition Therapeutics and architect of its discovery, preclinical and clinical science. Leveraging her 15 years of industry experience, she and her team discovered and developed the company's drug candidate, CT1812, and advanced it into clinical testing for the treatment of patients with mild-to-moderate Alzheimer's disease.

Prior to founding Cognition Therapeutics, Dr. Catalano was director of discovery biology for Acumen Pharmaceuticals, leading the team that discovered some of the industry's first drug candidates targeting A $\beta$  oligomers. Prior to this, at Rigel Pharmaceuticals, she led the team that pioneered the use of phenotypic screening to discover the Aurora kinase inhibitor R763, which was later licensed to Serono for use against solid tumors. While a scientist at Roche Palo Alto, she led the neurophysiology and neuroimaging groups along with an exploratory program in psychiatric disorders.

Dr. Catalano received her B.A. from Barnard College and Ph.D. from U.C. Irvine, with postdoctoral training at U.C. Berkeley and Caltech. She also holds an adjunct appointment at the University of Pittsburgh School of Medicine. She is an EY Entrepreneurial Winning Women class of 2015 recipient.